Home・Lista de Ações・TG Therapeutics Inc

TG Therapeutics Inc

Fechado

SetorSaúde

49.61 0.51

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

49.61

Máximo

50.08

Indicadores-chave
By Trading Economics
Rendimento	-3.3M 20M
Vendas	12M 205M
P/E Médio do Setor	16.143 68.51
EPS	0.05
Margem de lucro	9.651
Funcionários	399
EBITDA	-24M 28M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+28.9% upside

Dividendos
By Acuity
Próximos Ganhos	2 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.6B 7.1B
Abertura anterior	49.1
Fecho anterior	49.61

Sentimento de Notícias

By Acuity

17%

83%

22 / 340 Ranking em Healthcare

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2026, 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6 de ago. de 2026, 20:03 UTC

News

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5 de ago. de 2026, 19:56 UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4 de ago. de 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3 de ago. de 2026, 23:06 UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31 de jul. de 2026, 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 de jul. de 2026, 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 de jul. de 2026, 15:52 UTC

Social Media

News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 de jul. de 2026, 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 de jul. de 2026, 19:07 UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 de jul. de 2026, 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 de jul. de 2026, 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22 de jul. de 2026, 23:31 UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21 de jul. de 2026, 22:21 UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20 de jul. de 2026, 23:22 UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

28.9% parte superior

Previsão para 12 meses

Média 64.14 USD 28.9%

Máximo 86 USD

Mínimo 21 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para TG Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

22 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.